The statistical results of the preclinical validation of the QDEM and xMAP® 3-plex immunoassays detecting AMBP, PRDX2, and PARK7 markers as tools for diagnosis of lung cancer were practically identical. Here, PRDX2 is linked to lung carcinoma.